NTT Biopharma PIPELINE

Platform Technologies

Brain Delivery Ocular Delivery (Eyedrop Nanoformulation) Nucleic Acid Delivery Oral Peptide Delivery Active Targeting Nanoparticle

Brain Disease

NTT-001 DNA Plasmid (IV Injection for PD)

Cancer Therapy

NTT-002

Ocular Disease

NTT-003 (Eyedrop Formulation for Wet-AMD) ASO (Eyedrop Formulation for Wet-AMD) Therapeutic Peptide (Eyedrop Formulation for Dry-AMD)

Nucleic Acid Delivery Platform

Summary

• The MSN drug delivery platform offers a potential approach to deliver nucleic acids (e.g., ASO, mRNA, and DNA) for gene therapy.

• MSNs can transport payloads across the blood-brain and blood-ocular barriers to the brain or posterior segment of the eye, enabling gene therapy for CNS and retinal diseases.

• NTT’s MSN technology can reduce immunogenicity-related side effects triggered by typical LNP’s PEG.

Key Advantages of MSN Platform

• Larger Gene-Carrying Capacity Compared to AAV

• Optimizing Tissue Targeting and Penetration

• Resolving PEG Allergy Concerns

• Good Physical and Chemical Stability

• Convenient Modifications and Optimization

• Room for Patenting